IL-27R alpha/WSX-1/TCCR Antibody (191106) [Alexa Fluor® 488]

Human peripheral blood mononuclear cell (PBMC) lymphocytes were stained with Mouse Anti-Human CD3e APC-conjugated Monoclonal Antibody (Catalog # FAB100A) and either (A) Mouse Anti-Human IL-27 Ra/WSX-1/TCCR Alexa Fluor® 488-conjugated Monoclonal Antibody (Catalog # FAB14791G) or (B) Mouse IgG2BAlexa Fluor 488 Isotype Control (Catalog # IC0041G). View our protocol for Staining Membrane-associated Proteins.

• Reactivity: Hu
• Applications: Flow
• Clone: 191106
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 488

IL-27R alpha/WSX-1/TCCR Antibody (191106) [Alexa Fluor® 488] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human IL-27 R alpha /WSX‑1/TCCR
  Gly34-Lys516
  Accession # Q6UWB1
• Specificity: Detects human IL-27 R alpha /WSX‑1/TCCR in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human gp130 or recombinant mouse IL-27 Ra is observed.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Gene: IL27RA
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 5 uL/10^6 cells

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied in a saline solution containing BSA and Sodium Azide.
• Preservative: Sodium Azide

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-27R alpha/WSX-1/TCCR Antibody (191106) [Alexa Fluor® 488]

• class I cytokine receptor
• CRL1IL-27R
• Cytokine receptor-like 1
• IL-27 R alpha
• IL27R alpha
• IL27R
• IL27RA
• IL-27Ra
• IL-27R-alpha
• interleukin 27 receptor, alpha
• interleukin-27 receptor subunit alpha
• TCCR
• TCCRIL-27 receptor subunit alpha
• T-cell cytokine receptor type 1
• Type I T-cell cytokine receptor
• WSX-1
• WSX1IL-27R subunit alpha
• zcytor1

Background

IL‑27 R alpha (also known as WSX‑1 and TCCR) is a 96‑100 kDa member of the type I, group 2 cytokine receptor family (1 - 6). Mature IL‑27 R alpha  is a type I transmembrane glycoprotein that contains a 484 amino acid (aa) extracellular region, a 21 aa transmembrane segment and a 99 aa cytoplasmic domain. Consistent with type I cytokine receptors, the extracellular region contains four positionally conserved cysteine residues, a WSxWS motif (for receptor folding and ligand binding), and three fibronectin type III repeats. The intracellular domain contains a "box‑1" motif that may be involved with Janus kinases (3). One potential alternate splice form has been hypothesized that involves a 58 aa addition to the cytoplasmic domain and, based on mouse, a soluble 33 kDa splice form that shows a 20 aa substitution for aa 257‑636 may also occur in human (3, 7). The human IL‑27 R alpha extracellular region shares 63% amino acid identity with the mouse IL‑27 R alpha extracellular domain (2, 3). IL‑27 R alpha is expressed in mast cells, endothelial cells, NK cells, macrophages, monocytes, B cells, dendritic cells, and naïve T cells (1, 2, 4, 8). Typical of other class I cytokine receptor chains, the ligand binding IL‑27 R alpha molecule is known to heterodimerize with a signal‑transducing subunit (gp130) to form a functional IL‑27 receptor (9, 10). In addition, IL‑27 R alpha is reported to complex with CNTFR alpha and gp130 form a humanin receptor on neurons (7, 11), and to complex with gp130 and IL‑6 R to form a receptor for a p28:CLF heterodimeric cytokine on lymphocytes (12). Studies using IL‑27 R alpha /WSX‑1^‑/‑ mice reveal that IL‑27 has the ability to suppress T cell activity during infection, and to mediate an inhibition of both type 1 and type 2 T cell immunity (4, 13, 14). In particular, IL‑27 is known to act on naïve T cells, blocking their differentiation into a Th17 phenotype. Notably, cells committed to a Th17 phenotype, although they express a functional IL‑27 receptor, are unresponsive to the effects of IL‑27 (15). Activated T cells that are CD4⁺ and CD8⁺, and which express the IL‑27 receptor, can be induced by IL‑27 to form a double‑positive CD25⁺ FoxP3^‑ IFN‑ gamma plus IL‑10 secreting phenotype that both promotes and suppresses the inflammatory response (16).

1. Villarino, A.V. et al. (2004) J. Immunol. 173:715.
2. Chen, Q. et al. (2000) Nature 407:916.
3. Sprecher, C.A. et al. (1998) Biochem. Biophys. Res. Commun. 246:82.
4. Artis, D. et al. (2004) J. Immunol. 173:5626.
5. Yoshida, H. & Y. Miyazaki (2008) Int. J. Biochem. Cell Biol. 40:2379.
6. Yoshida, H. & M. Yoshiyuki (2008) Immunol. Rev. 226:234.
7. Hashimoto, Y. et al. (2009) Biochem. Biophys. Res. Commun. 389:95.
8. Holscher, C. et al. (2005) J. Immunol. 174:3534.
9. Pflanz, S. et al. (2004) J. Immunol. 172:2225.
10. Scheller, J. et al. (2005) Biochem. Biophys. Res. Commun. 326:724.
11. Hashimoto, Y. et al. (2009) Mol. Biol. Cell 20:2864.
12. Crabe, S. et al. (2009) J. Immunol. 183:7692.
13. Villarino, A. et al. (2003) J. Immunol. 170:645.
14. Hamano., S. et al. (2003) Immunity 19:657.
15. El-behi, M. et al. (2009) J. Immunol. 183:4957.
16. Fitzgerald, D.C. et al. (2007) Nat. Immunol. 8:1372.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: IL27RA
• Uniprot:
  • Q6UWB1()